Novo Nordisk A/S should conduct more studies before its long-acting insulin icodec can be approved for use in type 1 diabetics, a majority of US Food and Drug Administration advisory committee members said on 24 May.
Seven of 11 members of the Endocrinologic and Metabolic Drugs Advisory Committee said the company failed to demonstrate that the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?